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Summary
Background Preoperative and perioperative aromatase inhibitor (POAI) therapy has the potential to improve outcomes 
in women with operable oestrogen receptor-positive primary breast cancer. It has also been suggested that tumour 
Ki67 values after 2 weeks (Ki672W) of POAI predicts individual patient outcome better than baseline Ki67 (Ki67B). The 
POETIC trial aimed to test these two hypotheses.
Methods POETIC was an open-label, multicentre, parallel-group, randomised, phase 3 trial (done in 130 UK 
hospitals) in which postmenopausal women aged at least 50 years with WHO performance status 0–1 and hormone 
receptor-positive, operable breast cancer were randomly assigned (2:1) to POAI (letrozole 2·5 mg per day orally or 
anastrozole 1 mg per day orally) for 14 days before and following surgery or no POAI (control). Adjuvant treatment 
was given as per UK standard local practice. Randomisation was done centrally by computer-generated permuted 
block method (variable block size of six or nine) and was stratified by hospital. Treatment allocation was not 
masked. The primary endpoint was time to recurrence. A key second objective explored association between Ki67 
(dichotomised at 10%) and disease outcomes. The primary analysis for clinical endpoints was by modified 
intention to treat (excluding patients who withdrew consent). For Ki67 biomarker association and endpoint 
analysis, the evaluable population included all randomly assigned patients who had paired Ki67 values available. 
This study is registered with ClinicalTrials.gov, NCT02338310; the European Clinical Trials database, 
EudraCT2007-003877-21; and the ISRCTN registry, ISRCTN63882543. Recruitment is complete and long-term 
follow-up is ongoing.
Findings Between Oct 13, 2008, and April 16, 2014, 4480 women were recruited and randomly assigned to 
POAI (n=2976) or control (n=1504). On Feb 6, 2018, median follow-up was 62·9 months (IQR 58·1–74·1). 
434 (10%) of 4480 women had a breast cancer recurrence (280 [9%] POAI; 154 [10%] control), hazard ratio 0·92 
(95% CI 0·75–1·12); p=0·40 with the proportion free from breast cancer recurrence at 5 years of 91·0% (95% CI 
89·9–92·0) for patients in the POAI group and 90·4% (88·7–91·9) in the control group. Within the POAI-treated 
HER2-negative subpopulation, 5-year recurrence risk in women with low Ki67B and Ki672W (low–low) was 4·3% 
(95% CI 2·9–6·3), 8·4% (6·8–10·5) with high Ki67B and low Ki672W (high–low) and 21·5% (17·1–27·0) with high 
Ki67B and Ki672W (high–high). Within the POAI-treated HER2-positive subpopulation, 5-year recurrence risk in the 
low–low group was 10·1% (95% CI 3·2–31·3), 7·7% (3·4–17·5) in the high–low group, and 15·7% (10·1–24·4) in 
the high–high group. The most commonly reported grade 3 adverse events were hot flushes (20 [1%] of 2801 patients 
in the POAI group vs six [<1%] of 1400 in the control group) and musculoskeletal pain (29 [1%] vs 13 [1%]). No 
treatment-related deaths were reported.
Interpretation POAI has not been shown to improve treatment outcome, but can be used without detriment to 
help select appropriate adjuvant therapy based on tumour Ki67. Most patients with low Ki67B or low POAI-induced 
Ki672W do well with adjuvant standard endocrine therapy (giving consideration to clinical–pathological factors), 
whereas those whose POAI-induced Ki672W remains high might benefit from further adjuvant treatment or trials 
of new therapies.
Funding Cancer Research UK.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 
4.0 license.
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Introduction
The POETIC (Peri-Operative Endocrine Therapy—
Individualising Care) trial was designed to address 
two important hypotheses in the treatment of post-
menopausal women with oestrogen receptor-positive 
early breast cancer.
The first was that short duration presurgical endocrine 
therapy might improve clinical outcome. This hypothesis 
was plausible because 2 weeks’ preoperative endocrine 
therapy had been shown to markedly reduce proliferation 
in human breast cancer as measured by Ki67.1,2 
Longstanding experimental evidence had shown that the 
stimulatory effect of surgery on the growth of metastases 
in mice could be inhibited by perioperative endocrine 
therapy.3,4 Any improvement in long-term outcome 
following short exposure to preoperative or perioperative 
endocrine therapy would be achieved with no additional 
toxicity or resource implications and be of considerable 
clinical importance.
The second hypothesis concerned identifying which 
patients with hormone receptor-positive early breast 
cancer have a sufficiently good prognosis such that 
standard of care medical treatment, often comprising 
adjuvant endocrine therapy alone, was sufficient and 
which group should be considered for additional 
therapies. Traditional approaches to this problem had 
used standard prognostic parameters including size, 
grade, nodal involvement, and age, often integrated into 
a prognostic tool (eg, Nottingham Prognostic Index,5 
Adjuvant Online,6 NHS PREDICT7), but these merely 
provided the predicted probability of benefit for a patient 
population with given tumour and demo-graphic 
characteristics. More recently, genomic platforms have 
been developed aimed at providing more accurate 
prognostic and predictive information for the individual 
patient.8,9 However, these genomic tests are expensive, by 
no means universally available, and differ among 
themselves in terms of the information they provide.10
A simple test which predicts outcome after short 
duration preoperative endocrine therapy could therefore 
be helpful in accurately selecting appropriate treatment 
in the individual patient, if it incorporated an in-vivo 
response to aromatase inhibitor. A small neoadjuvant 
trial (IMPACT) had already suggested this might be 
feasible: results showed that tumour Ki67 after 2 weeks 
(Ki672w) of endocrine treatment predicted outcome better 
than at baseline (Ki67B), remaining significant in 
multivariable analysis, whereas Ki67B did not.11,12 Similar 
Research in context
Evidence before this study
Longstanding experimental evidence from 1989 led to the 
hypothesis that short duration, presurgical endocrine therapy 
for early oestrogen receptor-positive breast cancer might 
improve clinical outcome. We carried out a PubMed search for 
relevant clinical studies published from Jan 1, 1989 until 
Dec 31, 2019 using the terms “neoadjuvant endocrine”, “breast 
cancer”, “clinical trial”, and “presurgical and endocrine therapy”. 
No reasonably sized randomised trial addressed this issue by the 
time POETIC commenced recruitment in 2008. Subsequently, 
a randomised clinical trial reported that depot progesterone for 
5–14 days before surgery improved outcome in node-positive 
early breast cancer. Before the initiation of POETIC, two small 
clinical neoadjuvant trials, IMPACT and Z1031, reported that 
tumour Ki67 2–4 weeks after starting preoperative endocrine 
treatment predicted outcome better than baseline Ki67. POETIC 
was designed to establish whether the gain in prognostic 
accuracy merited routine application of presurgical endocrine 
therapy for this purpose. An additional PubMed search was done 
with “Ki67” added to the above search terms. One small study of 
low dose tamoxifen was identified, but this did not substantially 
add to the earlier evidence. Another modestly sized trial used to 
triage patients with 2–4 week Ki67>10% to chemotherapy and 
reporting the long-term outcome for those less than 10%, has 
led to a larger ongoing trial. One other large ongoing trial applies 
10% as a cutoff at 2 weeks of tamoxifen or an aromatase 
inhibitor for directing patients to different adjuvant therapy. The 
concept of complete cell cycle arrest has been developed as an 
additional possible cutoff for on-treatment Ki67.
Added value of this study
Results from POETIC suggest that 2 weeks’ preoperative 
endocrine therapy makes no perceptible improvement in 
long-term outcome, but was nevertheless a safe treatment 
practice. The trial confirmed the low risk of recurrence for those 
with a low baseline Ki67. In patients with a high baseline Ki67 
value (>10%) a biopsy 2 weeks after starting preoperative 
endocrine therapy provides additional clinical utility by 
predicting long-term outcomes. The trial documents the 
relationship of 2-week Ki67 with risk of recurrence for 
estimating whether the prognosis of individual patients is 
sufficiently good on endocrine therapy alone or whether 
additional treatment such as chemotherapy or new targeted 
therapies should be considered.
Implications of all the available evidence
The data show no reason for short-term presurgical treatment to 
be applied for its direct therapeutic potential, but support 
prescribing an aromatase inhibitor for the short-term period 
before breast cancer surgery in oestrogen receptor-positive 
tumours with a high proliferation rate to derive information on 
early endocrine responsiveness that can be used to predict a 
patient’s 5-year prognosis on standard adjuvant therapy. The 
clinical manoeuvres to incorporate this in the patient pathway 
with reliable quality assured Ki67 are straightforward and the 
measurement of Ki67 is inexpensive, potentially making this an 
attractive approach to estimating the prognosis of patients with 
early breast cancer.
†Mr Morden died in 
September, 2017
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results have subsequently been reported from another 
small trial comparing letrozole with tamoxifen13 and 
from a further trial comparing anastrozole, letrozole, and 
exemestane with one another.14 POETIC, with a much 
larger patient population, aimed to build on these 
findings to provide the definitive clinical evidence to 
inform future practice.
Methods
Study design and participants
This open-label, multicentre, parallel group, randomised, 
phase 3 trial recruited participants from 130 UK hospitals 
(appendix p 25–27). Eligible patients were postmeno-
pausal women (aged at least 50 years with amenorrhoea 
for more than 12 months, bilateral oophorectomy or 
hysterectomy, or had been on hormone replacement 
therapy within the previous 12 months, and with follicle-
stimulating hormone concentrations in the postmeno-
pausal range if aged less than 55 years) with oestrogen 
receptor-positive or progesterone receptor- positive 
(Allred ≥3, H-score ≥2, or ≥1% of positive cells, assessed 
in local pathology laboratories), HER2-positive or HER2-
negative (assessed locally), operable primary breast 
cancer and no evidence of metastatic spread investigated 
according to local guidelines. If palpable, a tumour of 
any size was sufficient, otherwise requiring an ultrasound 
size of at least 1·5 cm. Women required WHO 
performance status 0–1 and an indication for standard 
adjuvant endocrine therapy. Required staging investi-
gations were according to local practice with no additional 
trial specific investigations. Exclusion criteria were 
typical for this patient population. Previous endocrine 
therapy or chemotherapy was not allowed, nor was 
concurrent use of hormone replacement therapy or any 
other oestrogen-containing medication (within 4 weeks 
of randomisation). No previous use of oestrogen implants 
at any time, current, continuous, long-term systemic 
steroid usage, or treatment with an unlicensed or 
investigational drug within 4 weeks of randomisation 
was allowed. Patients with invasive malignancy diagnosed 
within the previous 5 years or any severe co-incident 
medical disease were ineligible (appendix p 1).
Patients provided written informed consent before 
enrolment. POETIC was sponsored by the Institute 
of Cancer Research (ICR) and Royal Marsden NHS 
Foundation Trust and approved by the London–South 
East Research Ethics Committee (reference 08/H1102/37) 
and managed and analysed by the ICR Clinical Trials and 
Statistics Unit (ICR-CTSU; appendix p 1 for study 
oversight details). The protocol is in the appendix.
Randomisation and masking
Participants were randomly allocated (2:1) to perioperative 
aromatase inhibitor (POAI) treatment or no perioperative 
treatment (control) by computer-generated permuted 
block method (variable block size six or nine) derived 
centrally by ICR-CTSU using its dedicated randomisation 
system, stratified by hospital. To randomly assign a 
patient, staff at the recruiting site telephoned ICR-CTSU 
and thus had no knowledge of future treatment 
assignment. The allocation ratio weighted trial 
information to study of biological perioperative drug 
effects, in particular to assess how these effects relate to 
long-term outcome. No placebo was used; clinicians and 
patients were not masked to treatment allocation, but 
central laboratory staff were masked.
Procedures
POAI was a non-steroidal aromatase inhibitor in 
standard dosage (oral anastrozole 1 mg per day or oral 
letrozole 2·5 mg per day); choice of agent was declared 
by each participating hospital at trial outset. Before 
randomisation, all patients had excisional surgery 
prebooked for around 2 weeks (minimum 10 days) later 
to ensure timing of surgery was not biased by treatment 
allocation. POAI was to commence immediately after 
randomisation allowing duration of treatment before 
surgery to be as close as possible to 14 days. If surgery 
was delayed, the pretreatment duration was extended. 
Treatment continued without interruption until 14 days 
after surgery.
All non-trial adjuvant therapy, laboratory investigations, 
and disease staging were established on clinical grounds 
according to standard of care local practice (appendix p 1). 
All patients had pretreatment mammography and breast 
ultrasound according to local diagnostic practice. In 
December, 2010, the independent data monitoring 
committee expressed caution relating to the potential 
influence of POAI therapy on tumour grade measured at 
surgery. In February, 2011, a letter to investigators, 
followed by an approved protocol amendment, recom-
mended that local multidisciplinary teams gave due 
consideration to other factors, including pretreatment 
grade on diagnostic core where available, when 
considering use of adjuvant chemotherapy.
Follow-up data were submitted annually to ICR-CTSU; 
disease-related events, second cancers and deaths were 
reported on occurrence. There was no specific safety 
endpoint. Adverse event data were restricted to 
three meno pausal symptoms (hot flushes, sweating, and 
musculoskeletal pain) at baseline, surgery, and at follow-
up 2 weeks postsurgery (assessed using National Cancer 
Institute Common Terminology Criteria for Adverse 
Events version 3) as the safety profiles of the aromatase 
inhibitors used were well established. Serious adverse 
events were reported or recorded (as per protocol). 
Participants were able to withdraw from the trial at any 
time for any reason.
Formalin-fixed paraffin-embedded tissue samples were 
required before randomisation (baseline) and at surgery. 
Baseline samples could be a core-cut diagnostic biopsy, 
a subsequent research core-cut biopsy, or sections from 
the diagnostic sample. At surgery, samples could be either 
core biopsies or sections cut from the routine excision.
See Online for appendix
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Tissue samples were processed, stored, and analysed 
for Ki67 staining centrally in the Ralph Lauren Centre for 
Breast Cancer Research at the Royal Marsden NHS 
Foundation Trust. Ki67 was analysed immunohisto-
chemically in a core biopsy taken at baseline (Ki67B), and 
in either a core biopsy or the excision biopsy taken at 
surgery (Ki672W), and was estimated as the percentage of 
cancer cells staining positive. We used MIB1 as the 
primary antibody to Ki67 and detection was done with 
the REAL EnVision system, both from DAKO (Glostrup, 
Denmark until 2016; now Agilent Technologies, Didcot, 
UK). Scoring was according to methodology including 
between-batch quality control procedures as described by 
the International Ki67 in Breast Cancer Working Group 
Party.15 Analysis of 2-week samples from the control 
group was restricted to a randomly selected subset since 
minimal change from baseline was expected.16
Outcomes
The primary endpoint was time to recurrence (time from 
randomisation to local, regional, or distant tumour 
recurrence or death from breast cancer without previous 
notification of relapse) with second primary cancers 
and intercurrent deaths censored. Secondary clinical 
endpoints included relapse-free survival (as per time to 
recurrence but also including deaths from any cause as 
events), time to local recurrence (time from random-
isation to first confirmed local recurrence, censoring at 
previous distant recurrence, second primary cancer, or 
death), time to distant recurrence (time from random-
isation to first confirmed distant recurrence or breast 
cancer death without previous relapse, censoring at 
second primary cancer or intercurrent death) and overall 
survival (time from randomisation to death from any 
cause). Breast cancer-free survival duplicated the 
definition of time to recurrence, and was listed in the 
protocol in error.
Ki67 was evaluated as a biomarker in relation to its 
effect on predicting disease outcomes (one of the trial’s 
two key objectives) and as the molecular secondary 
endpoint to assess proliferation rate at baseline (Ki67B) 
and at surgery (Ki672w), thus assessing the impact of 
POAI. The additional molecular secondary endpoint of 
gene expression profile at core biopsy and at surgical 
excision is not reported here as data analysis is ongoing.
Statistical analysis
The sample size assumed the proportion of patients with 
recurrence by 5 years would be low (approximately 10%) 
given known recurrence rates for similar populations.17,18 
With 4350 patients it would be possible to detect a 
3% improvement in time to recurrence at 5 years 
(10% to 7% recurrences) with 91% power (two-sided α of 
5%). The sample size was increased originally from 4000 
to 4350 patients to allow for underestimation of the 
relapse rate potentially owing to patients dying from 
other causes before breast cancer relapse. This change 
was endorsed by the trial steering committee and 
independent data monitoring committee and managed 
via a protocol amendment approved on Dec 31, 2012.
Analyses relating to clinical endpoints were done 
according to modified intention-to-treat—removing 
patients who subsequently withdrew consent for use of 
data. For analyses that assessed the predictive value of 
Ki67B and Ki672W, the population was defined as all 
randomly assigned patients who had paired Ki67 values 
available. Patients who did not have primary breast surgery 
as planned were censored at the date of that decision.
Baseline demographic details, tumour characteristics, 
adjuvant treatment, and Ki67 data are presented with 
descriptive statistics. Protocol compliance between 
treatment groups (time from randomisation to surgery 
and number of inpatient days for surgery) was compared 
using Wilcoxon rank-sum tests; differences in tumour 
grade at surgery were assessed using a χ² test for trend in 
prespecified analyses. Worst grade of adverse events and 
serious adverse reactions to POAI were summarised 
descriptively. Ki67B and Ki672W were reported by HER2 
status. Analysis of percentage change between Ki67B and 
Ki672W used Wilcoxon sign rank tests within treatment 
groups and Wilcoxon rank-sum test between treatment 
groups. In a post-hoc exploratory analysis, following 
initial planned analyses on the trial data, a multivariable 
logistic regression model was created, using a forward 
stepwise approach, to determine factors affecting 
chemotherapy use.
For survival-related endpoints, Kaplan-Meier curves 
were plotted and treatment groups compared with the 
log-rank test. Hazard ratios (HRs) and 95% CIs were 
calculated within Cox proportional hazards regression 
models, with HRs of less than one taken to favour POAI. 
The proportional hazards assumption was assessed 
using Schoenfeld residuals and was found to hold. 
Comparisons between treatment groups were made with 
and without adjustment for progesterone receptor status 
(positive, negative, unknown), HER2 status (positive, 
negative, unknown), presurgical tumour grade (G1, G2, 
and G3), pathological tumour size (continuous), 
presurgical histological type (ductal, lobular, special 
type), nodal status (N0, N1–3, and N4+), age at 
randomisation (continuous) and vascular invasion (yes, 
no). Subgroup analyses were done for baseline clinical 
characteristics and presented using a forest plot.
Associations between Ki67B and Ki672W and time to 
recurrence were done separately in the POAI and control 
groups with the principal focus being to study the on-
treatment effect of POAI. A post-hoc analysis of all 
patients combined for Ki67B was included for com-
pleteness. Assessment of Ki67 in the control group was 
considered of low additional value because patients were 
not exposed to perioperative treatment and because of the 
lack of association between POAI and time to recurrence. 
Survival analysis included adjust ment for clinical factors 
as mentioned previously, except for HER2 status which 
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was a stratifying factor. HER2-positive tumours have a 
different pattern of recurrence and were typically addi-
tionally treated with specific HER2-targeted therapy. 
To explore associations between Ki67 and disease outcome 
in the POAI group, Ki67 scores were dichotomised 
and patients divided into four groups as follows: low–low 
(Ki67B and Ki672W <10%); high–low (Ki67B ≥10%, 
Ki672W <10%); high–high (Ki67B and Ki672W ≥10%); 
and low–high (Ki67B <10%, Ki672W ≥10%). Few POAI 
patients were classified into the low–high group. These 
are reported for completeness but not further analysed as 
their apparent response is probably due to measurement 
variability around the dichotomisation cut-point. Post-hoc 
subgroup analyses explored associations between Ki67 
and disease outcome by chemotherapy use and age with a 
view to avoid confounding of interpretation. In addition 
to the predefined 10% Ki67 dichotomisation, chosen to 
ensure consistency with other neoadjuvant trials,12,14 other 
cut-points were explored using Harrell’s C coefficient19 
including that for complete cell cycle arrest (CCCA; 
Ki67 ≤2·7%20).
Previous analyses21 of change in Ki67 in 679 control 
group patients with paired samples available indicated 
that in patients with a core-cut surgery sample the median 
proportional reduction was −4·1% (IQR −27·8 to 34·8), 
whereas in those with a resection sample at surgery, the 
median proportional reduction in Ki67 between baseline 
and surgery was −17·7% (IQR −44·2 to 12·7) in contrast 
with an earlier small pilot study.16 From these findings, it 
was assumed that, for a given surgical sample, change in 
Ki67 score would be proportionally approximately 15% 
less if the sample was core-cut rather than resection 
(eg, 10% reduction with resection sample translated to 
8·5% for core-cut). To account for this difference, Ki67 
data and the analyses linking Ki67 and time to recurrence 
were done with Ki672W corrected according to surgical 
sample type. Ki672W scores from resection samples were 
increased proportionally by 15%. This correction factor 
was derived (and used) in control participants and 
similarly applied to participants in the POAI group. The 
correction was also made for patients for whom surgical 
sample type was unknown. For cases where Ki672W was 
0%, no adjustment was made.
This manuscript describes the primary endpoint 
analysis, time to recurrence after a 5-year median follow-
up for both hypotheses; first by randomised POAI 
allocation and second exploring the ability of Ki67 to 
predict disease outcome. No formal interim analyses 
were planned or done before the primary analysis. For 
this purpose, a database snapshot was taken on 
Aug 8, 2017 for data presented at the San Antonio Breast 
Cancer Conference 2017 and updated with a second 
database snapshot taken on Feb 6, 2018. All analyses 
were done by means of Stata (version 13.1). A p value of 
less than 0·05 was deemed to be significant.
This study is registered with ClinicalTrials.gov, 
NCT02338310; the European Clinical Trials database, 
EudraCT2007-003877-21; and the ISRCTN registry, 
ISRCTN63882543.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all of the data in the study and had final responsibility for 
the decision to submit for publication.
Results
Between Oct 13, 2008, and April 16, 2014, 4486 patients 
were entered from 130 UK centres. Six patients 
subsequently withdrew consent for data to be used and 
therefore 4480 patients (2976 POAI, 1504 control) were 
included in the modified intention-to-treat analysis 
(figure 1).
Median age at randomisation was 67·1 years 
(IQR 61·5–74·8), 2536 (57%) of 4480 patients had a 
tumour size up to 2 cm, and all but eight (<1%) patients 
were confirmed locally to have hormone receptor-positive 
tumours (table 1). 23 (1%) of 4480 patients did not have 
surgery as planned (16 patients in the POAI group and 
seven in the control group; figure 1). Adherence to trial 
Figure 1: Trial profile
4486 patients randomly assigned
2980 allocated to perioperative aromatase
 inhibitor
2976 allocated to perioperative aromatase
 inhibitor
2610 had baseline Ki67 data available
2528 had paired Ki67 data available
4 withdrew consent for all data to be
 used 
82 did not have surgical Ki67 data
 available
16 surgery cancelled
 8 cardiac risk or anaesthetic concerns
 8 metastatic disease or new primary 
 cancer discovered
366 did not have baseline Ki67 data
 available
1506 allocated to control
1504 allocated to control
1303 had baseline Ki67 data available
678 had paired Ki67 data available
2 withdrew consent for all data to be
 used 
625 did not have surgical Ki67 data
 available
7 surgery cancelled
 3 cardiac risk or anaesthetic concerns
 2 metastatic disease or new primary 
  cancer discovered
 1 surgery declined
 1 death before surgery
201 did not have baseline Ki67 data
 available
Articles
1448 www.thelancet.com/oncology   Vol 21   November 2020
treatment and timelines are shown in the appendix (p 14). 
177 (6%) of 2976 patients did not have the protocol 
defined duration of POAI (preoperatively <10 days or 
>21 days, post operatively <10 days). The most common 
reasons were 63 (2%) had their surgery changed, 35 (1%) 
had less owing to adverse events (16 were in the 
presurgical period), and 30 (1%) had less owing to patient 
choice or omission. Surgical details and postsurgery 
tumour characteristics were well balanced between 
groups with the exception of pathological tumour grade, 
which was higher in the control group (p<0·0001; 
table 1). Adjuvant radiotherapy and anti-HER2 therapy 
were given after surgery with similar frequency for the 
two groups and in line with UK standard of care. 
Adjuvant chemo therapy was given to 770 (26%) of 
2957 patients in the POAI group and 460 (31%) of 
1493 patients in the control group (appendix p 15) with 
multivariable analyses attributing this to differences 
observed in postsurgical grade (appendix p 16). Following 
surgery, most (POAI 2507 [86%] of 2960 patients; control 
1186 [81%] of 1497 patients) women were prescribed 
aromatase inhibitor monotherapy (appendix p 17).
With 62·9 months’ median follow-up (IQR 58·1–74·1), 
434 (10%) of 4480 women had a breast cancer recurrence 
(POAI 280 [9%] of 2976 patients, control 154 [10%] of 
1504 patients; table 2) with no significant difference 
observed between the treatment groups (HR 0·92, 
95% CI 0·75–1·12; p=0·40, adjusted HR 0·96, 
0·77–1·19; p=0·70; figure 2A) with the proportion free 
from breast cancer recurrence at 5 years of 91·0% 
(89·9–92·0) in the POAI group and 90·4% (88·7–91·9) 
in the control group. Subgroup analyses according to 
clinical characteristics, including nodal status, were 
consistent with the overall effect (appendix p 2). 
Likewise, no significant differences between treatment 
groups were observed for relapse-free survival, time to 
local recurrence, and time to distant recurrence (table 3). 
Second breast cancer primaries developed in 26 (<1%) 
of 2976 women in the POAI group compared with 
24 (2%) of 1504 in the control group. 561 patients had 
died (POAI 365 [12%] of 2976; control 196 [13%] of 1504). 
Almost half of deaths were attributable to a non-breast 
cancer cause; none were treatment related (table 2). 
There was no difference in overall survival between 
treatment groups. 5-year overall survival was 88·9% 
(95% CI 87·7–90·1) in the POAI group versus 88·9% 
(87·2–90·5) in the control group (unadjusted HR 0·94, 
95% CI 0·79–1·12; p=0·50, adjusted HR 0·91, 
0·75–1·10; p=0·33; figure 2B).
Selected menopausal symptoms were assessed in 
4201 (94%) of 4480 women, with higher symptom rates 
observed for POAI (appendix p 18). The most commonly 
reported grade 3 adverse events were hot flushes (20 [1%] 
of 2801 patients in the POAI group vs six [<1%] of 1400 in 
the control group) and musculoskeletal pain (29 [1%] vs 
13 [1%]). 11 patients each reported a single serious adverse 
reaction (appendix p 19); all in the POAI group. The most 
Demographics at randomisation and 
tumour characteristics from the 
diagnostic core














Age group at randomisation, years
<50 9 (<1%) 3 (<1%) ·· ··
50–59 579 (19%) 291 (19%) ·· ··
60–69 1245 (42%) 609 (40%) ·· ··
70–79 808 (27%) 429 (29%) ·· ··
≥80 335 (11%) 172 (11%) ·· ··






Anastrozole 954 (32%) 483 (32%) ·· ··
Letrozole 2022 (68%) 1021 (68%) ·· ··
Hormone receptor status
Positive 2971 (100%) 1501 (100%) ·· ··
Negative 4 (<1%) 1 (<1%) ·· ··
Missing 1 (<1%) 2 (<1%) ·· ··
HER2 status
Positive ·· ·· 317 (11%) 152 (10%)
Negative ·· ·· 2606 (88%) 1316 (88%)
Unknown or missing ·· ·· 37 (1%) 29 (2%)
Hormone receptor and HER2 status*
Hormone receptor-positive
HER2 positive ··· ·· 317 (11%) 152 (10%)
HER2 negative ·· ·· 2606 (88%) 1316 (88%)
HER2 unknown ·· ·· 37 (1%) 29 (2%)
Hormone receptor-negative
HER2 negative ·· ·· 4 (<1%) 1 (<1%)
Histological type
Ductal† 2404 (81%) 1198 (80%) 2364 (80%) 1199 (80%)
Lobular 428 (14%) 224 (15%) 454 (15%) 236 (16%)
Special type‡§ 105 (4%) 58 (4%) 124 (4%) 50 (3%)
Ductal carcinoma in situ 
or lobular carcinoma in 
situ¶
0 0 3 (<1%) 2 (<1%)
Not breast cancer|| 0 0 1 (<1%) 0
Not known 39 (1%) 24 (2%) 14 (<1%) 10 (1%)
Tumour grade
G1 417 (14%) 234 (16%) 465 (16%) 184 (12%)
G2 1757 (59%) 843 (56%) 1968 (66%) 838 (56%)
G3 521 (18%) 279 (19%) 502 (17%) 463 (31%)
GX 0 1 (<1%) ·· ··
Not known** 278 (9%) 145 (10%) 17 (1%) 6 (<1%)
Missing 3 (<1%) 2 (<1%) 8 (<1%) 6 (<1%)
Tumour size, cm††
≤2 1666 (56%) 870 (60%) 1372 (46%) 671 (45%)
>2–5 1238 (42%) 599 (40%) 1448 (49%) 745 (50%)
>5 54 (2%) 28 (2%) 129 (4%) 74 (5%)
Missing 18 (1%) 7 (<1%) 11 (<1%) 7 (<1%)
(Table 1 continues on next page)
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common were pulmonary embolism (n=3) and 
musculoskeletal pain (n=3).
3913 (87%) of 4480 participants had Ki67B data available. 
2528 (85%) of 2976 patients in the POAI group and 
678 (45%) of 1504 in the control group had paired Ki67B 
and Ki672W data available (figure 1). In 2316 (72%) of 
3206 participants with paired Ki67 data, the surgical 
sample was a resection (1834 [73%] of 2528 patients in 
the POAI group; 474 [70%] of 678 patients in the control 
group) or the surgical sample type was unknown (six in 
the POAI group and two in the control group) and the 
Ki672W scores for these resections and unknown surgical 
sample types were corrected as described. 688 (27%) of 
2528 POAI and 202 (30%) of 678 control patients’ surgical 
sample type was core-cut biopsy.
The median Ki67B score in the 3913 of 4480 patients 
with a sample available was 15·2% (IQR 8·6–26·0; POAI 
15·3% [8·5–26·4]; control: 14·9% [8·6–25·1]). Ki67B 
values were different between HER2-negative and HER2-
positive tumours (median 14·3% [IQR 8·2–24·6] in 
HER2-negative tumours, median 26·6% [17·0–37·4] in 
HER2-positive tumours; p<0·0001). After 2 weeks of 
POAI, Ki67 was significantly suppressed compared with 
little change in the control group. Ki672W was markedly 
lower in the HER2-negative tumours compared with 
HER2-positive tumours (appendix p 3). In the control 
group, given the little overall change, Ki672W was again 
lower in the HER2-negative tumours than in HER2-
positive tumours (appendix p 3).
In patients with HER2-negative tumours in the POAI 
group (2235 of 2528 patients), 209 (9%) time to recurrence 
events were reported. For the time to recurrence endpoint, 
women with Ki67B less than 10% (732 [33%] of 
2235 patients) had a better prognosis than those with a 
Ki67B of at least 10% (1503 [67%] of 2235 patients; 
appendix p 20). Women whose Ki672W remained high 
(high–high group) were significantly more likely to have a 
recurrence than those whose Ki672W had dropped below 
10% (high–low group; unadjusted HR 2·59, 95% CI 
1·93–3·47; p<0·0001, adjusted HR 2·10, 1·48–2·98; 
p<0·0001; figure 3A). Within the POAI-treated HER2-
negative subpopulation, 5-year recurrence risk in women 
with low Ki67B and Ki672W (low–low) was 4·3% (95% CI 
2·9–6·3), 8·4% (6·8–10·5) with high Ki67B and low Ki672W 
(high–low) and 21·5% (17·1–27·0) with high Ki67B and 
Ki672W (high–high). Within the POAI-treated HER2-
positive subpopulation, 5-year recurrence risk in the low–
low group was 10·1% (95% CI 3·2–31·3), 7·7% (3·4–17·5) 
in the high-low group, and 15·7% (10·1–24·4) in the 
high–high group. Adding a high versus low classification 
at 2 weeks segregated groups in relation to their baseline 
Ki67 (appendix p 21).
The HER2-negative POAI-treated subpopulation post-
hoc exploratory analyses relating to the combined effects 
of age and chemotherapy use suggested that in patients 
with Ki67B of at least 10%, who did not receive adjuvant 
chemotherapy, the residual Ki672W (high or low) conferred 
a differential effect on prognosis as assessed by time to 
recurrence for both those aged less than 70 years and 
aged at least 70 years (appendix pp 4–9). Numbers were 
too small to fully define effects for the corresponding 
group (ie, Ki67B ≥10%) who did receive chemotherapy.
In patients with HER2-negative breast cancer in the 
control group, 56 time to recurrence events were reported 
in the 597 of 678 patients for whom Ki672W was available. 
There was no difference in time to recurrence between 
the high–high and high–low groups (appendix pp 10, 22).
Demographics at randomisation and 
tumour characteristics from the 
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(Continued from previous page)
Definitive breast surgery
Mastectomy ·· ·· 1051 (36%) 503 (34%)
Conservative surgery ·· ·· 1902 (64%) 992 (66%)
Missing ·· ·· 7 (<1%) 2 (<1%)
Definitive axillary surgery
Yes ·· ·· 2911 (98%) 1470 (98%)
Clearance ·· ·· 916 (31%) 468 (31%)
Sampling ·· ·· 287 (10%) 150 (10%)
Sentinal lymph node 
biopsy
·· ·· 1708 (58%) 852 (57%)
No ·· ·· 42 (1%) 25 (2%)
Missing ·· ·· 7 (<1%) 2 (<1%)
Nodal status
N0 ·· ·· 1815 (61%) 892 (60%)
N1–3 ·· ·· 801 (27%) 434 (29%)
N4+ ·· ·· 334 (11%) 165 (11%)
Missing ·· ·· 10 (<1%) 6 (<1%)
Vascular invasion
Yes ·· ·· 813 (27%) 445 (30%)
No ·· ·· 1990 (67%) 981 (66%)
Not reported ·· ·· 143 (5%) 63 (4%)
Missing ·· ·· 14 (<1%) 8 (1%)
Multi-focal disease
Yes ·· ·· 381 (13%) 223 (15%)
No ·· ·· 2563 (87%) 1266 (85%)
Missing ·· ·· 16 (1%) 8 (1%)
Data are n (%) and median (IQR). Surgery details exclude patients for whom surgery was permanently cancelled. 
*One patient (perioperative aromatase inhibitor) with hormone receptor status unknown was HER2 negative; the 
remaining two patients (control) with hormone receptor status unknown also had HER2 status unknown. †Ductal 
includes patients with mixed ductal and lobular tumours. ‡Special types on the diagnostic core include mucinous, 
papillary, tubular, metaplastic carcinoma, microcapillary, anaplastic with basaloid nuclear pattern. §Special types from 
surgery specimen include mucinous, papillary, tubular, endocrine cell carcinoma, pure special type, metaplastic 
carcinoma clear cell, and basaloid, tubular, and cribiform carcinoma. ¶Presurgical histological types for these patients 
were coded as ductal carcinoma. ||Prehistological type was not known (this patient is recorded as ineligible). **Some 
UK hospitals do not routinely report grade on the diagnostic core. ††Presurgery this measurement is either by 
ultrasound or clinical examination. Patients are eligible if they have either a palpable tumour (clinical examination) of 
any size or a tumour with an ultrasound size of ≥1·5 cm. 618 patients had tumour size <1·5 cm, of which 607 had a 
tumour confirmed as palpable.
Table 1: Baseline characteristics
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A post-hoc sensitivity analysis in the HER2-negative 
subgroup combining the baseline data for POAI and 
control gave a 5-year recurrence risk of 4·7% (95% CI 
3·5–6·3) for low Ki67B and 11·5% (95% CI 10·1–13·1) 
for high Ki67B (appendix p 24).
Prespecified exploratory analysis in the HER2-negative 
subgroup suggested an optimal cut-point around 15–20% 
for Ki67B and around 6–8% for Ki672W and that using the 
CCCA threshold for Ki672W had prognostic discrimination 
(appendix pp 11–13).
In patients with hormone receptor-positive, HER2-
positive breast cancer in the POAI group (273 [10%] of 
2528 patients), 33 time to recurrence events were 
reported. 143 women in the Ki67 high–high group had a 
recurrence compared with 94 in the high–low group, 
although the difference was not significant (unadjusted 
HR 2·08, 95% CI 0·88–4·90; p=0·093, adjusted HR 1·83, 
0·71–4·73; p=0·21; figure 3B). Similar to the HER2-
negative group, absolute risk of recurrence at 1, 3, and 
5 years was higher in the high-high group than in the 
high–low group (appendix p 23). 5-year recurrence risk 
in the low-low group was 10·1% (95% CI 3·2–31·3), 
7·7% (3·4–17·5) in the high–low group, and 15·7% 
(10·1–24·4) in the high–high group. In the 70 women 
with HER2-positive breast cancer in the control group, 
nine time to recurrence events were reported.
Discussion
POETIC is, to our knowledge, the largest trial of its kind 
to assess the potential of POAI therapy in patients with 
postmenopausal, hormone receptor-positive early breast 
cancer and it did not show any significant long-term 
improvement in disease outcomes with this approach. 
This was despite preclinical experimental evidence in a 
mouse model suggesting the contrary.3,4 A smaller phase 3 
clinical trial, which reported after POETIC was initiated, 
randomly assigned operable breast cancer patients 
(n=976, 50% hormone receptor-positive, 45% hormone 
receptor-negative, and 5% hormone receptor unknown) 
to surgery or an intramuscular injection of depot 
hydroxyprogesterone 500 mg 5–14 days before surgery; 
no significant benefit was observed in the overall 
population (HR 0·87, 95% CI 0·68–1·09; p=0·23), but 
the results suggested a hypothesis-generating potential 
disease-free survival improvement in node-positive 
subgroups (HR 0·72, 0·54–0·97; p=0·02).22 In contrast, 
consistent with the overall finding, POETIC showed no 
suggestion of long-term outcome improvement with 
POAI overall or in the node-positive subgroup.
In POETIC, the frequency of chemotherapy was 
slightly lower in patients in the POAI group than in those 
in the control group. Multivariable regression supported 
the suggestion that this was probably because of 
multidisciplinary teams being influenced by pathological 
tumour grade, which was on average lower in the patients 
in the POAI group. This absolute difference was small 
however (5%), and since the overall event rate was less 
than 20% would have had an imperceptible effect on 
outcome comparisons.
On a pragmatic note, it is common practice to start 
some patients on preoperative endocrine therapy if there 
has to be a significant delay in surgery for any reason. 
Despite not showing any statistical evidence of clinical 
benefit, our results provide reassurance that there is no 
detriment to this practice.
The second aim of this trial was to explore whether the 
measurement of tumour Ki67 2 weeks after starting 
treatment could predict disease outcome better than 
baseline Ki67 alone, thus providing the basis of a simple 
and inexpensive test to personalise adjuvant treatment 
in patients with hormone receptor-positive, HER2-







Any disease-related first event
Yes 541 (18%) 309 (21%)
No 2435 (82%) 1195 (80%)
Event contributing to primary endpoint (time to recurrence)
Total 280 (9%) 154 (10%)
Local recurrence (isolated) 25 (1%) 13 (1%)
Distant recurrence* 236 (8%) 131 (9%)
Breast cancer death† 19 (1%) 10 (1%)
Other event
Total 261 (9%) 155 (10%)
Breast second primary cancer 26 (1%) 24 (2%)
Non-breast second primary cancer 136 (5%) 80 (5%)
Intercurrent death 99 (3%) 51 (3%)
Deaths
Total 365 (12%) 196 (13%)
Breast cancer 201 (7%) 110 (7%)
Other (intercurrent deaths) 164 (6%) 86 (6%)
Cardiovascular 41 (1%) 25 (2%)
Other cancer 59 (2%) 35 (2%)
Respiratory 37 (1%) 15 (1%)
Sepsis 14 (<1%) 5 (<1%)
Other‡ 13 (<1%) 6 (<1%)
Data are n (%). If more than one first event was reported on the same date, it was 
included in the row here according to the following order of priority: distant 
recurrence, local recurrence, breast second primary cancer, non-breast second 
primary cancer, and intercurrent death. *Distant recurrence row included patients 
for whom distant recurrence is reported within 6 weeks of local recurrence. 
†Included 25 patients (18 perioperative aromatase inhibitor, seven in the control 
group) with unknown cause of death and no previous event; one patient had a 
second primary cancer before unknown cause of death and was not included here. 
‡Other causes in the perioperative aromatase inhibitor group (n=13) were 
accident (n=2), acute kidney injury, Alzheimer’s disease, ascending aortic 
aneurysm, haematemesis secondary to gastric ulcer, hepatic cirrhosis, multiorgan 
failure, myelofibrosis, old age with vascular deterioration and chronic kidney 
disease, portal hypertension, a fall, ascites, evidence of cirrhosis, postoperative 
complications relating to pituitary tumour operation, and renal failure; other 
causes in the control group (n=6) were complications post laparotomy, dementia, 
diabetes, meningioma, subdural haematoma, and suicide.
Table 2: Disease-related first events and deaths
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that 2-week on-treatment Ki67 predicted outcome better 
than baseline and, unlike baseline, was significant in 
multivariable analysis.12 POETIC has provided evidence 
for the clinical validity of on-treatment aromatase 
inhibitor Ki672W in addition to Ki67B to predict those with 
high residual risk of recurrence in spite of standard-of-
care therapy. At the initiation of POETIC, we believed 
that the evidence was insufficient to withhold or direct 
therapy on the basis of the Ki672W. Our results provide an 
early indication of endocrine sensitivity or resistance 
including for the large number of patients who are not 
routinely considered for adjuvant chemotherapy.
Separate clearly defined adjuvant treatment pathways 
for HER2-positive and HER2-negative breast cancers 
now exist and we therefore analysed these groups 
separately when considering prognostic risk. The 
HER2-positive subgroup was small with relatively few 
events. Focus for exploratory analysis was therefore on 
the HER2-negative subgroup, which comprised approxi-
mately 90% of the POETIC population.
Figure 2: Kaplan-Meier survival curve by randomised treatment group for time to recurrence (A) and overall survival (B)















































































Unadjusted hazard ratio 0·94 (95% CI 0·79–1·12); p=0·50
Time from randomisation (years)
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Data are n (%), hazard ratio (95% CI); p value, and % (95% CI). Models adjusted for progesterone receptor status 
(positive, negative, unknown), HER2 status (positive, negative, unknown), presurgical tumour grade (G1, G2, and G3), 
pathological tumour size (continuous), presurgical histological type (ductal, lobular, special type), nodal status 
(N0, N1–3, and N4+), age at randomisation (continuous), and vascular invasion (yes, no). Test for proportionality for 
relapse-free survival, p=0·69; for time to local recurrence, p=0·97, and for time to distant recurrence, p=0·52.
Table 3: Summary of disease-related endpoints
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Previously, it had been shown that patients with a low 
Ki67B have a better prognosis than those with a high 
Ki67B value.23 POETIC confirmed this in a larger 
prospective population, dichotomising Ki67B at 10% with 
5-year recurrence risk in HER2-negative patients in the 
POAI group of 4·4% for low Ki67B and 11·8% for high 
Ki67B. To our knowledge, this is the first large published 
dataset that makes use of the Ki67 scoring methodology 
recommended by the International Ki67 in Breast 
Cancer Working Group; the strong association of Ki67 at 
baseline with prognosis served as a clinical validation of 
that methodology.15 Patients whose Ki67B was low did well 
on standard of care, with approximately 85% of those 
receiving endocrine therapy alone. It could be the case 
that if the patient’s clinical pathological features led to 
chemotherapy being given, this approach might have 
contributed to the good outcomes. But irrespective of 
adjuvant treatment, it is reasonable to conclude that 
Ki672w did not add significant prognostic or predictive 
information in this subgroup.
In contrast, for patients whose tumours had a high 
baseline Ki67 in the POAI group, 73% had a low Ki672w 
2 weeks after starting treatment; those patients had a 
better prognosis at 5 years than those who continued to 
have a high Ki672W (8·4% vs 21·5% 5-year recurrence 
risk). To what extent could this observation be applied to 
clinical practice?
The answer to this question is influenced by the 
limitations of this trial. The first concerns the optimal 
cutoff for Ki67, and we have shown that dichotomising 
for cutoffs other than 10% merit further exploration. The 
second limitation concerns interpreting the data in 
relation to age and chemotherapy usage. Older age has 
already been shown to be an independent prognostic 
factor in breast cancer24 and POETIC patients aged at 
least 70 years had poorer outcomes than those aged 
below 70 years. Since a substantial minority (26%) of 
POAI patients had adjuvant chemotherapy, this could be 
a potential confounding factor in the interpretation of 
Ki672W in relation to prognosis and prediction of the value 
of endocrine therapy alone. To address this, we repeated 
our analyses in patients according to their receipt of 
adjuvant chemotherapy. This confirmed a persisting 
worse outcome for tumours high–high after 2 weeks of 
an aromatase inhibitor compared with high–low in the 
74% of patients not receiving chemotherapy. In the 
corresponding groups who received chemotherapy, 
numbers were insufficient to determine a prognostic 
Ki67 effect or to define a plausible beneficial chemo-
therapy effect.
In the two-thirds of patients below the age of 70 years 
not receiving chemotherapy, the overall outcome in 
terms of recurrence risk was better, probably reflecting 
the choice of omitting chemotherapy for better prognosis 
patients. But the key point was that in this population of 
patients non-confounded by chemotherapy, 21% with 
high Ki67B remained high at surgery (high–high) and 
those had 11·2% 5-year recurrence risk (arguably 
meriting chemotherapy in addition), compared with the 
low–low groups in which recurrence by 5 years was only 
1·6% and the high–low group in which recurrence by 
5 years was only 2·9% (indicating that additional 
chemotherapy would be of no clinically relevant benefit). 
This exploratory outcome must be interpreted with 
caution but further supports the prognostic value of 
measuring Ki67 at 2 weeks.
Similar findings were observed for patients aged at 
least 70 years. Only 59 of those patients received 
chemotherapy, too few to provide statistical confidence in 
the relationship between Ki67 and outcome. In those 
Figure 3: Kaplan-Meier survival curve for time to recurrence by Ki67B and Ki672W for patients with hormone 
receptor-positive and HER2-negative breast cancer (A) and hormone receptor-positive, HER2-positive breast 
cancer (B) in the perioperative aromatase inhibitor group
Low–low=Ki67B and Ki672W <10%. High–low=Ki67B ≥10% and Ki672W <10%. High–high=Ki67B and Ki672W ≥10%. 
B=baseline. 2w=2weeks. 28 patients with hormone receptor-positive breast cancer and HER2-negative breast 
cancer and four patients with hormone receptor-positive and HER2-positive breast cancer in the low-high group 
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Unadjusted hazard ratio 2·59 (95% CI 1·93–3·47); p<0·0001
Unadjusted hazard ratio 2·08 (95% CI 0·88–4·90); p=0·093
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aged at least 70 years who did not receive chemotherapy, 
there was again a large difference in outcome between 
the high–low and high–high groups (5-year recurrence 
risk 12·3% vs 34·5%), again supporting the discriminatory 
power of measuring Ki67 at 2 weeks, even though the 
absolute risks were greater.
The prespecified Ki672w 10% cut-point was chosen for 
consistency with ongoing clinical trials (ALTERNATE 
[NCT01953588]; ADAPT [NCT01779206]). The relationship 
of Ki672w with recurrence risk is continuous and as 
illustrated by our analysis by means of CCCA, other cut-
points might be selected if appropriate for a specific use 
(eg, assessing the value of well-tolerated additional 
treatment).
In conclusion, in POETIC, giving perioperative endo-
crine therapy with an aromatase inhibitor had no 
significant effect on long-term outcome. The trial also 
showed that using Ki67B and aromatase inhibitor on-
treatment Ki672w could help guide adjuvant treatment 
decisions. First, we believe that we have identified a 
subgroup with a low baseline Ki67 who have a sufficiently 
good prognosis that the majority will do well on standard 
endocrine therapy alone (except perhaps for a minority as 
dictated by other clinical–pathological factors) and who do 
not require a repeat 2-week biopsy. Second, giving POAI to 
the subgroup with high baseline Ki67 can differentiate two 
groups of patients according to their 2-week Ki67 value: 
those who convert to a low Ki67 might not need anything 
beyond adjuvant endocrine therapy (taking consideration 
of other clinical-pathological factors), whereas those with a 
high Ki67 that has remained high, should be considered 
for further adjuvant treatments and trials. There are, of 
course, now several commercially available genomic 
platforms developed to provide the same kind of prognostic 
and predictive information for the individual patient.8,9 But 
these tests are expensive, they often involve central testing 
of tissue, which has to be sent long distances with 
inevitable time delay, and results can differ between the 
platforms. Ki67 as used in POETIC potentially offers an 
inexpensive, easy and quick alternative in situations in 
which genomic testing is not readily available.
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